Pharmaceutical composition
AssigneeTakeda Chemical Industries, Ltd.
InventorsHitoshi Ikeda, Takashi Sohda, Hiroyuki Odaka
Life of this patent
Estimating the term…
Abstract
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Claims16
A pharmaceutical composition comprising an insulin sensitivity enhancer In combination with a biguanide, wherein the insulin sensitivity enhancer is selected from the group consisting of:
- (1) 5-(4-(2-(3-ethyl-2-pyridyl)ethoxy)benzyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (2) 5-(4-(2-(4-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (3) 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (4) 5-(4-(2-(6-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (5) (R)-(+)-5-(3-(4-(2-(2-furyl)-5-methyl-4-oxazolylmethoxy)-3-methoxyphenyl)p ropyl)-2,4-oxazolidinedione or its pharmacologically acceptable salt.
- (6) 5-((3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl)methyl)-2,4thiazolid inedione or its sodium salt,
- (7) 5-((4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)phenyl)methyl)-2,4-thi azolidinedione or its sodium salt.
- (8) 5-(2-(5-methyl-2-phenyl-4-oxazolylmethyl)benzofuran-5-ylmethyl)-2,4-oxazol idinedione,
- (9) 5-(2-naphthalenylsulfonyl)-2,4-thiazolidinedione, and
- (10) 5-((4-(2-methyl-2-pyridylamino)ethoxy)phenyl)-methyl)-2,4-thiazolidinedion e or its pharmacologically acceptable salt.
A method for treating diabetes in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of an insulin sensitivity enhancer in combination with a biguanide, wherein the insulin sensitivity enhancer is selected from the group consisting of:
- (1) 5-(4-(2-(3-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (2) 5-(4-(2-(4-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (3) 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (4) 5-(4-(2-(6-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt,
- (5) (R)--(+)-5-(3-(4-(2 -(2-furyl)-5-methyl-4-oxazolylmethoxy)-3-methoxyphenyl)propyl-2,4-oxazolid inedione or its pharmacologically acceptable salt,
- (6) 5-((3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl)methyl)-2,4-thiazoli dinedione or its sodium salt.
- (7) 5-((4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)phenyl)methyl)-2,4-thi azolidinedione or its sodium salt,
- (8) 5-(2-(5-methyl-2-phenyl-4-oxazolylmethyl)benzofuran-5-ylmethyl)-2,4-oxazol idinedione,
- (9) 5-(2-naphthalenylsulfonyl)-2,4-thiazolidinedione, and
- (10) 5-((4-(2-methyl-2-pyridylamino)ethoxy)phenyl)-methyl)-2,4-thiazolidinedion e or its pharmacologically acceptable salt.
Dependencies are inferred from the claim text.